- BeiGene’s 4Q revenue was $634.4 million, an increase of 67% year on year, but fell short of the estimated $643.3 million.
- The company’s product revenue was $630.5 million, which is an 86% increase from the previous year, but also missed the estimated $647.2 million.
- Collaboration revenue was significantly lower than estimated, coming in at $3.88 million instead of the projected $38.6 million.
- BeiGene’s gross margin was 83.2%, slightly above the estimated 82.2%.
- Research and development expenses were $493.99 billion, compared to $446.0 million the previous year, and slightly higher than the estimated $493.3 million.
- Sales, general and administrative expenses were $416.5 million, higher than the estimated $400.5 million.
- Loss per share was 27 cents, an improvement from the previous year’s loss of 33 cents per share.
- John V. Oyler, Chairman, Co-Founder and CEO at BeiGene, stated that the company has solidified its leadership in hematology with the successful global launch of BRUKINSA, particularly in the U.S. and Europe.
- Currently, BeiGene has received 21 buys, 2 holds, and 0 sells.
A look at BeiGene Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
BeiGene, Ltd. is a biopharmaceutical company that is focused on developing and commercializing drugs for the treatment of cancer. According to Smartkarma’s Smart Scores, the company has a long-term outlook that is looking positive. With a score of 4 for growth and 5 for resilience, this indicates that BeiGene has strong potential for future growth and is well-positioned to withstand any challenges that may arise. However, the company’s value and momentum scores are lower, at 2 and 2 respectively, which suggests that investors may want to closely monitor the company’s performance before making any investment decisions.
Despite its lower scores in value and momentum, BeiGene’s overall outlook is still promising. The company has a strong focus on developing and commercializing drugs for the treatment of cancer, which is a constantly growing market. With a score of 1 for dividend, BeiGene may not be the best choice for investors looking for immediate returns, but its focus on growth and resilience make it a potentially lucrative long-term investment. Overall, BeiGene’s commitment to innovation and its strong position in the biopharmaceutical industry make it a company to watch in the coming years.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
